Glac Biotech has been focused on probiotic research and development for over 15 years. To meet the increasing order demands, the company has recently expanded a modern probiotic ODM factory in Hsinchu. This move not only enhances the capacity of the existing production lines but also adds the capability to produce encapsulated products to meet the growing global market demand.

Glac Biotech stated that with over 15 years of experience in the field of probiotics and postbiotics, the company is a renowned biotech firm both domestically and internationally. Considering the global rise in health consciousness and the growing trend towards natural products, there is an increasing annual demand for capsule dosage forms in clinic and pharmacy channels, as well as a significant rise in the demand for additive-free health supplements from e-commerce and major brands in recent years. Understanding the advantages and opportunities that the capsule market can bring, the company decided to expand its production base to seize global business opportunities.

▲ Glac Biotech adds capsule production capacity to meet the growing global market demand. Glac Biotech / Provided

The establishment of the Hsinchu plant not only increases the capacity for probiotic powder packs but also expands the existing capsule production line with the addition of fully automatic capsule machines, increasing annual capacity by five times. Under constant temperature and humidity conditions throughout the plant, it ensures the production of healthy and high-quality raw materials, positioning Glac Biotech as a leading probiotic ODM manufacturer. Not only has the company's original probiotic ODM capability been upgraded, but the new production line also brings international business opportunities. Combining the robust energy of the R&D team, they have created PRONULIFE® functional probiotics and the award-winning postbiotic Totipro®, expanding the probiotic landscape and establishing an all-in-one CDMO probiotic ODM service.

Glac Biotech's General Manager, Huang Sheng-hong, stated that this is a critical strategic expansion for the company. The Hsinchu plant will utilize the most advanced production technology and automation systems, not only improving and expanding production efficiency but also ensuring high-quality ODM services to create competitive products for domestic and international brand enterprises.

With the rapid growth of the global health product market, Glac Biotech's expanded Hsinchu plant will undoubtedly become a strong driving force for the company's future growth. It will enhance internal product supply capacity and further expand its global market sales network. In addition, Glac Biotech's probiotic and postbiotic raw materials have garnered significant international attention. In the future, Glac Biotech will continue to invest in probiotic research to meet the diverse needs of global consumers.

For more information, visit Glac Biotech's website: https://en.glac.com.tw/